Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood-2017-05-781450
Abstract: Eculizumab, a humanized anti-complement C5 monoclonal antibody (mAb) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complement pathway required for serum bactericidal activity (SBA). Because treated patients are… read more here.
Keywords: eculizumab treatment; treatment impaired; treatment; blood ... See more keywords